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Results
Correlation In Pain, Depression, and Anxiety
- In four weeks, the patient’s anxiety, pain, and depression decreased 
and remained thereafter. 
Abstract
Pediatric recruitment included a patient
with acute lymphocytic leukemia. Blood
chemistry and blood indices were analyzed
and the patient reported physical, mental,
and emotional statuses in a PROMIS
questionnaire. At baseline, week 1, week 2,
and week 3 Fatigue fluctuated over time
while there was a decrease in anxiety, pain,
and depression. Suspected fatigue
biomarkers were not quantified.
Methods & Materials
This study is a preliminary report of an
active IRB approved research protocol.
Children diagnosed with ALL were recruited
into the study. Participants were asked to
complete a Patient Reported Outcome
Measurement Information System (PROMIS)
questionnaire before starting chemotherapy
and 1, 2, and 3 weeks after chemotherapy.
Blood samples on each visit were collected
and sent to the laboratory for analysis.
Conclusions
• Cannot link ApoE to CRF
• Chemotherapy medications may have
influenced data collected
• Anemia and blood chemistry are not
likely to cause fatigue in patient
• Links between fatigue, blood lipids, and
hemoglobin/hematocrit were observed
• No hard conclusions because of case
study
• Further investigation required
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Introduction
Acute Lymphoblastic Leukemia is a blood
cancer in which the bone marrow produces
too much lymphocytes (B or T cells). This
can affect the production of red blood cells,
platelets, and other bone marrow
derivatives. Patients undergoing
chemotherapy typically report feeling tired
or fatigue. There is no known cause of
fatigue. However, we suspect that
Apolipoprotein E may be a biomarker
candidate.
Background
• Apolipoprotein E is a lipid carrier
molecule that helps transport lipids
through the bloodstream. Certain alleles
have been linked to Alzheimer's disease
and more recently inflammation in
trauma.
• Cancer- and cancer-treatment-related
fatigue is the ongoing exhaustion that
limits a person to perform daily activities
that were previously enjoyed before.
Patient-Reported Outcomes Measurement
Information System (PROMIS) scores for
baseline (designated visit=1), week 1
(visit=2), week 2 (visit=3), and week 3
(visit=4). Raw data was converted into T-
scores provided by PROMIS statistical
measurements.
Patient Recruitment
Some of the limitations of the limitations encountered in this
project was patient recruitment. Only one patient was
recruited throughout the entirety of the given timeline. The
patient is ten (10) years old and was diagnosed with ALL
previous to recruitment. Sole patient recruitment into the
study changed original plans for study into case study.
The patient received chemotherapy. Medication included
Vincristine, Doxorubicin, Methatrexate, Dexamethasone, and
Pegaspargase.
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Triglycerides
• Self-reported fatigue T-scores and lab report of hemoglobin and 
hematocrit levels in patient. The first week experienced a 47.5% 
increase in fatigue. The second week, fatigue levels dropped. On the 
third week, fatigue levels increased to about the same as the second 
week.
• Hemoglobin levels increased the first week by 15.0% and decreased 
on the second week. 
• Hematocrit ratios increased on the first week by 3.8% and decreased 
slightly on the second week.
• Triglyceride levels decreased the second week and increased back to 
baseline the third week.
• Cholesterol levels increased the second week and returned to 
baseline the fourth week. 
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Fatigue & Anemia and 
Fatigue & Blood Lipid Levels
Fatigue levels fluctuated over
four weeks. The graphs
indicate there is a correlation
between increase/decrease in
fatigue and Hb and Hct levels.
Blood chemistry indicates
that there is no anemia in the
patient, though. Triglycerides
and cholesterol levels also
had correlations with fatigue
levels. Triglycerides had a
positive correlation while
cholesterol had a negative
correlation. Inflammation
marker, Apolipoprotein E, was
not analyzed for.
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General Results
• Blood chemistry levels were reported to be within normal ranges.
This includes sodium, potassium, calcium, carbon dioxide
concentrations, urea, liver enzymes, and glucose.
• Blood chemistry panel indicates that there is a positive trend with
all tested substances. All substances increased from baseline to
week 1 and decreased from week 2 to week 3.
• Self-reported physical mobility and peer-relationship scores had a
negative correlation.
